Robert J. Gould - Apr 1, 2022 Form 4 Insider Report for Fulcrum Therapeutics, Inc. (FULC)

Role
Director
Signature
/s/ Curt Oltmans, as attorney-in-fact for Robert J. Gould
Stock symbol
FULC
Transactions as of
Apr 1, 2022
Transactions value $
-$1,537,756
Form type
4
Date filed
4/5/2022, 07:00 PM
Next filing
Apr 11, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FULC Common Stock Options Exercise $270K +34.5K +6.8% $7.84 541K Apr 1, 2022 Direct F1
transaction FULC Common Stock Sale -$828K -34.5K -6.37% $24.03* 507K Apr 1, 2022 Direct F1, F2
transaction FULC Common Stock Options Exercise $56.7K +7.24K +1.43% $7.84 514K Apr 4, 2022 Direct F1
transaction FULC Common Stock Sale -$174K -7.24K -1.41% $24.02* 507K Apr 4, 2022 Direct F1, F3
transaction FULC Common Stock Options Exercise $412K +52.6K +10.37% $7.84 559K Apr 5, 2022 Direct F1
transaction FULC Common Stock Sale -$1.27M -52.6K -9.4% $24.26* 507K Apr 5, 2022 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FULC Stock Option (right to buy) Options Exercise $0 -34.5K -10.62% $0.00 290K Apr 1, 2022 Common Stock 34.5K $7.84 Direct F1, F5
transaction FULC Stock Option (right to buy) Options Exercise $0 -7.24K -2.49% $0.00 283K Apr 4, 2022 Common Stock 7.24K $7.84 Direct F1, F5
transaction FULC Stock Option (right to buy) Options Exercise $0 -52.6K -18.59% $0.00 230K Apr 5, 2022 Common Stock 52.6K $7.84 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.17, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.05, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.75, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.
F5 This option was granted on January 22, 2019 and is scheduled to vest in equal quarterly installments from January 1, 2019 through December 31, 2022.